Forum Agenda

July 23-24

Global Session on Small Nucleic Acid Drug Innovation

Stay tuned

Meeting Planner
Zicai Liang:Chairman and CEO, Ribo Life Science
Yan Chang:Chairman and President, InnoStar
Howe Li:Chairman, Livius Biotech

 

July 23

 

09:00-09:30   The Third Wave of Modern Pharmaceuticals – From the Prosperity of Hepatic Delivery to the Surging Advance of Extrahepatic Delivery in Small Nucleic Acid Pharmaceuticals
Zicai Liang:Chairman and CEO, Ribo Life Science


09:30-09:50   Differentiated Project Initiation and Pipeline Layout Strategies for Small Nucleic Acid Drugs Based on Disease Mechanisms
Dong Xie:Chairman 、CEO 、CSO, Frontier Biotechnologies Inc.


09:50-10:10   Applications and Progress of siRNA Drugs in the Field of Lipid Management
Lianshan Zhang:Director & Executive Vice President, Hengrui Medicine


10:10-10:30   Dual-Target Oligonucleotides Enable Novel Therapeutic Strategies for Comorbid Metabolic Disorders
Xinjian Liu:CSO & Vice President,  BeBetter Med Inc.


10:30-11:00   Break


11:00-11:15   Development of antisense oligonucleotides for HBV cure
Chris Yang:Co-founder & CSO, AusperBio


11:15-12:00   Roundtable Discussion: The Next Five Years of the Small Nucleic Acid Drug Industry
Quan Gan (Moderator):Managing Director, SDIC Investment
Zicai Liang:Chairman and CEO, Ribo Life Science
Dong Xie:Chairman, CEO & CSO, Frontier Biotechnologies Inc.
Dongxu Shu:Founder, Chairman & CEO, Argo Biopharma
Xin Xie:Executive Director & Senior Vice President, Sino Biopharmaceutical
Nannan Chang:Managing Director, GL Ventures


12:00-13:00   Lunch


13:00-13:15   Developing a New Generation of siRNA Drugs Centered on AI
Xiangrui Gao:Head of Nucleic Acid Drug R&D, XtalPi


13:15-13:30   TBD
Qian Li:Chairman, Beijing Sun-novo Pharmaceutical Research


13:30-13:45   siRNA: Reshaping the Therapeutic Landscape of Chronic Diseases
Qunsheng Ji:CEO, Sirius Therapeutics


13:45-14:00   siRNA vs ASO: Two Paths of Oligonucleotide Innovation for Chronic Hepatitis B
Qing Zhu:Senior Vice President,Brii Bio


14:00-14:15   Toxicological Evaluation of Small Nucleic Acid Drugs: Key Considerations and Case Analysis
Naping Tang:Vice President, InnoStar


14:15-14:30   How Anlong Biotech Stands Out in the Small Nucleic Acid Industry
Chunlin Zhao:Founder, AnlongBio; Founding Partner, Anlong Fund


14:30-14:45   Development and Application of Small Nucleic Acid Drugs in the Cardiovascular Field
Xiaoming Zou:CEO, Bisirna Therapeutics


14:45-15:00   Breakthrough in delivery platform advances the application of small nucleic acid drugs in chronic diseases
Lijuan Wang:CSO, Shenzhen Salubris Pharmaceuticals


15:00-15:20   Coffee Break


15:20-15:35   Extrahepatic Delivery and Clinical Research of Small Nucleic Acid Drugs
Yuanyu Huang:Founder & Chairman, Rigerna Therapeutics


15:35-15:50   Novel Cross-Modal Drug R&D Technologies Based on Small Nucleic Acids
Xingquan Ma:Co-President, ChemPartner


15:50-16:05   Early Clinical Trial Design and Safety Evaluation of Nucleic Acid Drugs
Ruihua Dong:Director of Clinical Research Ward, Beijing Friendship Hospital, Capital Medical University


16:05-16:20   Systematic Solutions for Small Nucleic Acids: From Lab-Scale Trials to Commercial Production
Yanhua Wang:Product Director, Small Nucleic Acid Solution Division, Tofflon


16:20-16:35   Neural Mouse Models: Bridging Preclinical Efficacy to Clinical Outcomes
Shuxin Xu:Deputy Director of Preclinical Service Platform, Head of Metabolism Pipeline & Chief Scientist of Metabolism, GemPharmatech


16:35-16:50   Antisense makes sense
Haisheng Wang:Founder & CEO, SicaGene


16:50-17:30   Roundtable Discussion: Technical Challenges and Breakthroughs of Small Nucleic Acid Drugs
Hao Li (Moderator):Chairman, Livius Biotech
Xiaobin Zhao:Founder, Chairman & General Manager, HaiChang Biotech
Xiaoye Su:Dean of Research Institute, CSPC Pharmaceutical Group
Haizhou Zhang:Senior Vice President, GeneScience Pharmaceuticals (Changchun)
Yun Zhu:General Manager, YUN HO BIO
 Hu Xiaomin:Former Senior Pharmacist/Senior Reviewer at CDE (Center for Drug Evaluation)

 

July 24

 

09:00-09:15   MicroRNA (miRNA) Therapies for Aging-Related Diseases
Hao Li:Chairman, Livius Biotech


09:15-09:30   Beyond the Liver: SCAD and LiCO—Clinically Validated Extrahepatic Delivery Platforms for Oligonucleotide Therapeutics
Longcheng Li:Founder, Chairman & CEO, Ractigen Therapeutics


09:30-09:45   Innovative siRNA Therapeutics for Pulmonary Diseases
Yi Huang:General Manager, Innovative Drug Division, Gowell Pharmaceutical


09:45-10:00   Introduction to Sirnaomics’ GalAhead Delivery Platform and Clinical Progress of STP122G
Weiwei Tian:VP, Sirnaomics


10:00-10:15   Overview of Youcare Pharmaceutical’s Oligonucleotide Innovation Platform and R&D Pipeline
Gengshen Song:Director, Deputy General Manager & Dean of Pharmaceutical Research Institute, Youcare Pharmaceutical Group Co.,Ltd.


10:15-10:30   AI-Driven Targeted RNA Therapeutics Platform
Rong Xin:CEO, RecoRNA


10:30-10:50   Break


10:50-11:05   Conjugation Empowerment: Delivery Advancements & Multi-Target Hurdles for Next-Generation siRNA Drugs
Chengjiang Zhao:Co-Founder, Youjia Biotech


11:05-11:20   From bench to bed –case study of siRNA drugs for metabolism/CVD
Jinqiao Wan:Chairman CEO ,Leaderna


11:20-12:00   Roundtable Discussion: Innovation of Small Nucleic Acid Drugs from the Investor's Perspective
Fei Qi (Moderator):Executive Director, Legend Capital
Zhiping Cui:General Manager, New Drug Fund, Fosun Health Capital; Chairman, Hepa Thera
Li Wang:Member of Investment Banking Committee & Head of Healthcare Department, Guotai Haitong Securities
Junhong Li:Partner, Lapam Capital
Wei Ding:Partner, Apricot Capital


12:00-13:00   Lunch


13:00-13:15   Extrahepatic Targeted Delivery Technologies Based on lncRNA
Xu Song:Founder, lncTAC


13:15-13:30   Oligonucleotide Drug Development: Translational Barriers and Clinical Countermeasures in First-in-Human Trials and Proof-of-Concept Studies
Junlong Wang:General Manager, InnoClinic


13:30-13:45   Small Nucleic Acids, Grand Era — Global Industrial Transformation and the Empowerment Journey of Cytiva
Yi Zhu:Gene Therapy Technology Lead, Cytiva China


13:45-14:00   Extreme Manufacturing and Its Applications in Nucleotide Monomer Synthesis
Fang Zhao:Research Professor, East China Normal University


14:00-14:15   CMC Research of Nucleic Acid Therapeutics: Manufacturing and Quality Control from Starting Phosphoramidite Monomers to Drug Substances
Qing Li:CEO, Tianjin Pharma, Desano Group


14:15-14:30   Development of Nucleic Acid Drugs Based on Novel Nucleic Acid Modifications and Exploration of Ophthalmic Applications
Chuan Zhang:Founder & CEO, Rehydration Therapeutics


14:30-14:45    Analytical Characterization Challenges and Solutions for Nucleic Acid Medicines
Lei Ma:Biopharmaceutical Application Specialist, Waters